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Abstract
Introduction The prevalence of chronic hypertension is
increasing in pregnant women. Beta-blockers are among
the most prevalent anti-hypertensive agents used in early
pregnancy.
Objective The objective of this study was to investigate
whether first-trimester use of beta-blockers increases the
risk of specific congenital anomalies in offspring.
Methods A population-based case-malformed control
study was conducted in 117,122 registrations of congenital
anomalies from 17 European Concerted Action on Con-
genital Anomalies and Twins (EUROCAT) registries par-
ticipating in EUROmediCAT with data for all or part of the
period between 1995 and 2013. Associations previously
reported in the literature (signals) were tested and an
exploratory analysis was performed to identify new signals.
Odds ratios of exposure to any beta-blocker or to a beta-
blocker subgroup were calculated for each signal anomaly
compared with two control groups (non-chromosomal,
non-signal anomalies and chromosomal anomalies). The
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exploratory analyses were performed for each non-signal
anomaly compared with all the other non-signal anomalies.
Results The signals from the literature (congenital heart
defects, oral clefts, neural tube defects and hypospadias)
were not confirmed. Our exploratory analysis revealed that
multi-cystic renal dysplasia had significantly increased
odds of occurring after maternal exposure to combined
alpha- and beta-blockers (adjusted odds ratio 3.8; 95%
confidence interval 1.3–11.0).
Conclusion Beta-blocker use in the first trimester of
pregnancy was not found to be associated with a higher risk
of specific congenital anomalies in the offspring, but a new
signal between alpha- and beta-blockers and multi-cystic
renal dysplasia was found. Future large epidemiological
studies are needed to confirm or refute our findings.
Key Points
The results of this large EUROmediCAT study refute
the signals reported in the literature but do suggest
that multi-cystic renal dysplasia might be associated
with combined alpha- and beta-blocker use in the
first trimester of pregnancy.
Future large studies are needed to confirm or refute
these findings.
The individual risk for a pregnant woman will be low
and should be balanced against the benefits of beta-
blocker treatment during pregnancy.
1 Introduction
The prevalence of chronic hypertension is increasing in
general but also in pregnant women, with obese (body mass
indexC 30) and older mothers (agedC 35 years) at an
increased risk [1, 2]. Chronic hypertension, defined as
hypertension (blood pressureC 140/90 mmHg) present
before pregnancy or diagnosed before the 20th week of
gestation, occurs in approximately 1–5% of all pregnancies
but this may be an underestimation [1, 3, 4]. For severe
hypertension, anti-hypertensive treatment is necessary to
prevent serious complications in both mother and child [4].
Beta-blockers are among the most prevalent classes of anti-
hypertensive agents used in early pregnancy, as evidenced
by a drug utilisation study in USA where 30% of all anti-
hypertensive medications used in the first trimester were
beta-blockers [5]. In addition, the use of beta-blockers
increased over time in two American studies [5, 6]. From
studies in the UK and USA, it is estimated that 0.6% of all
pregnant women are exposed to beta-blockers in the first
trimester of pregnancy [6, 7].
Despite the increased use of beta-blockers in pregnancy,
there is only limited information on their possible terato-
genic effects. Beta-blockers could reduce uteroplacental
blood flow and could therefore lead to congenital anoma-
lies in the offspring. Most beta-blockers were given the
former Pregnancy Letter Category C by the US Food and
Drug Administration, meaning that ‘‘risk cannot be ruled
out’’ [8] because experimental animal studies have shown
an adverse effect on the foetus or there have been no
adequate and well-controlled studies in humans. A recent
meta-analysis showed that first-trimester beta-blocker use
was associated with congenital heart defects [when dia-
betes was excluded or adjusted for, odds ratio (OR) 2.72,
95% confidence interval (CI) 1.90–3.90], cleft lip/palate
(OR 3.11, 95% CI 1.79–5.43) and neural tube defects (RR
3.56, 95% CI 1.19–10.67) [9]. However, it is difficult to
establish whether there is a true causal relationship
between beta-blocker use and congenital anomalies, as
many of the studies were underpowered, potentially biased
and heterogeneous.
We therefore aimed to investigate whether first-trimester
use of beta-blockers increases the risk of specific congen-
ital anomalies in offspring by using data from EURO-
mediCAT, a very large database, which has not previously
been used to study the effects of beta-blockers. The
EUROmediCAT network was set up to evaluate the safety
of medication use in pregnancy in relation to the risk of
congenital anomalies; it builds on an existing network of
population-based congenital anomaly registries in Europe
(European Concerted Action on Congenital Anomalies and
Twins, EUROCAT), which also have data on maternal
medication exposure in the first trimester of pregnancy
[10].
2 Methods
2.1 Study Design
We performed a case-malformed control study using data
from the EUROmediCAT database, in which we performed
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both a signal analysis to test associations that had previ-
ously been reported in the literature and an exploratory
analysis to identify possible new associations [11].
2.2 Literature Review
We first performed a literature review to identify associa-
tions that had been previously reported on maternal first-
trimester use of beta-blockers and congenital anomalies.
All original papers that were included in the meta-analysis
of Yakoob et al. were scrutinised [9]. In total, four original
studies (three case-control studies and one cohort study)
found statistically significant associations between first-
trimester use of all or specific beta-blockers and specific
congenital anomalies in the offspring [12–15] (Table 1).
In addition, we searched PubMed to identify original
studies that were published after Yakoob et al.’s literature
search in August 2011 [9]. The following search terms
were used: (‘‘Pregnancy’’[Mesh] OR ‘‘Pregnancy trimester,
First’’[Mesh] OR pregnan*[tiab]) AND (‘‘Adrenergic beta-
Antagonists’’[Mesh] OR ‘‘Adrenergic beta-Antago-
nists’’[Pharmacological Action] OR beta adrenergic
antag*[tiab] OR adrenergic beta antag*[tiab] OR beta
block*[tiab] OR betablock*[tiab] OR beta adrenergic
block*[tiab] OR beta adrenergic receptor block*[tiab] OR
beta receptor block*[tiab] OR alprenolol[tiab] OR
oxprenolol[tiab] OR pindolol[tiab] OR propranolol[tiab]
OR timolol[tiab] OR sotalol[tiab] OR nadolol[tiab] OR
mepindolol[tiab] OR carteolol[tiab] OR tertatolol[tiab] OR
bopindolol[tiab] OR bupranolol[tiab] OR penbutolol[tiab]
OR cloranolol[tiab] OR practolol[tiab] OR metoprolol[-
tiab] OR atenolol[tiab] OR acebutolol[tiab] OR betax-
olol[tiab] OR bevantolol[tiab] OR bisoprolol[tiab] OR
celiprolol[tiab] OR esmolol[tiab] OR epanolol[tiab] OR
s-atenolol[tiab] OR nebivolol[tiab] OR talinolol[tiab] OR
labetalol[tiab] OR carvedilol[tiab] OR ‘‘Antihypertensive
Agents’’[Mesh] OR antihypertensive*[tiab]) AND (‘‘Con-
genital Abnormalities’’[Mesh] OR ‘‘Prenatal Exposure
Delayed Effects’’[Mesh] OR congenital*[tiab] OR defor-
mit*[tiab] OR defect*[tiab] OR malformation*[tiab] OR
anomal*[tiab] OR side effect*[tiab] OR ‘‘adverse effects’’
[Subheading] OR ‘‘chemically induced’’ [Subheading] OR
adverse[tiab] OR abnormalit*[tiab] OR safety[tiab] OR
outcome[tiab] OR expos*[tiab] OR teratogen*[tiab]) NOT
(‘‘Animals’’[Mesh] NOT ‘‘Humans’’[Mesh]). On 22
December, 2016 there were 378 hits with a publication date
between 1 August, 2011 and present, of which 347 were
written in English (Fig. 1). This search identified one
additional original study reporting a possible association
between first-trimester use of non-selective beta-blockers
and severe hypospadias (OR 3.22, 95% CI 1.47–7.05),
although the effect was non-significant after multiple test-
ing adjustment [16] (Table 1).
2.3 Study Population
EUROCAT is a European network of population-based
registries set up in 1979 to perform epidemiological
surveillance of congenital anomalies [17]. EUROCAT
registries collect data on all pregnancy outcomes: live
births, foetal deathsC 20 weeks of gestational age (in-
cluding stillbirths) and terminations of pregnancy for foetal
anomalies (TOPFAs) with a major congenital anomaly.
Cases with a minor congenital anomaly are excluded from
the EUROCAT database [18]. EUROCAT methodology
and details of the member registries have been published
previously [19, 20]. The congenital anomalies are coded
using the International Classification of Diseases, 9th or
10th Revisions, with British Paediatric Association one-
digit extension and are grouped into EUROCAT subgroups
of congenital anomalies [17]. Up to nine congenital
anomalies can be registered together with text information.
EUROmediCAT is a daughter of EUROCAT [10] and
contains data from EUROCAT registries that also have
data on first-trimester medication exposure coded with the
Anatomical Therapeutic Chemical code (ATC code [21]).
There is no limit to the number of medications that can be
registered and text information can also be registered for
each medication exposure.
All EUROCAT registries participating in EURO-
mediCAT with data over all or part of the period
1995–2013 and with at least one registration in this period
with a confirmed first-trimester exposure to a beta-blocker
were eligible for inclusion in this study. We included 17
registries in 13 countries in this study with a total coverage
of 4,528,994 births: Odense (Denmark), Paris (France), Isle
de La Reunion (France), Tuscany (Italy), Emilia Romagna
(Italy), Northern Netherlands, Vaud (Switzerland), Zagreb
(Croatia), Malta, Antwerp (Belgium), Saxony Anhalt
(Germany), Mainz (Germany), Wales (UK), Norway,
South East Ireland, Basque Country (Spain) and Valencia
Region (Spain) (Table 2).
2.4 Exclusions and Definitions of Cases
and Controls
For this study, we excluded registrations with genetic
syndromes, teratogenic syndromes, skeletal dysplasias and
congenital skin disorders (n = 5777). In addition, we
excluded registrations in which the timing of beta-blocker
use was unknown (n = 41), registrations with maternal
hypertension but no use of anti-hypertensive medication
(n = 222), registrations with maternal diabetes and/or
insulin use during pregnancy (n = 1723), maternal epi-
lepsy and/or anti-epileptic medication use during preg-
nancy (n = 1180) and registrations with the use of highly
teratogenic medication (US Food and Drug Administration
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former Pregnancy Letter Category X, n = 17). In total, we
excluded 8713 (6.9%) registrations based on one or more
of these criteria. All exclusions are presented in the
flowchart in Fig. 2.
For the signal analysis, cases were defined as registra-
tions with a congenital anomaly reported in the literature as
associated with beta-blocker use in the first trimester of
pregnancy: congenital heart defects, with atrial septal
defects and pulmonary valve stenosis as specific sub-
groups; cleft lip with or without cleft palate (CL/P), cleft
palate (CP); neural tube defects (NTD) and hypospadias.
Registrations with the Pierre Robin sequence were exclu-
ded from the CP group. Controls were all other EURO-
mediCAT registrations and were divided into a non-
chromosomal non-signal anomaly group and a chromoso-
mal anomaly group according to the EUROCAT subgroups
Table 1 Literature signals for specific congenital anomalies after exposure to beta-blockers in the first trimester of pregnancy
Congenital anomaly Medication type Exposed
cases
Exposure period
(months of gestation)
Type of study (type
of controls)
OR adj (95%
CI)
References
Cleft lip with or
without cleft palate
Oxprenolol 6 2, 3 CC (population
controls)
4.2
(1.8–10.0)
[15]
Cleft lip with or
without cleft palate
Oxprenolol 6 2, 3 CC (malformed
controls)
2.8
(1.2–6.6)
[15]
Posterior cleft palate Oxprenolol 3 3, 4 CC (population
controls)
3.6$
(1.1–11.7)
[15]
Neural tube defect Pindolol 2 2 CC (population
controls)
5.8#
(1.3–26.4)
[14]
Congenital heart
defects
Atenolol, betaxolol, bisoprolol,
labetalol, metoprolol,
pindolol, propranolol
31 - 1, 1, 2, 3 CC (non-malformed
live births)
2.6¥
(1.2–5.3)
[12]
Pulmonary valve
stenosis
Atenolol, betaxolol, bisoprolol,
labetalol, metoprolol,
pindolol, propranolol
7 - 1, 1, 2, 3 CC (non-malformed
live births)
5.0¥
(1.8–13.8)
[12]
Ostium secundum
atrial septal defect
Atenolol, betaxolol, bisoprolol,
labetalol, metoprolol,
pindolol, propranolol
8 - 1, 1, 2, 3 CC (non-malformed
live births)
2.8¥
(1.1–7.5)
[12]
Ostium secundum
atrial septal defect
Labetalol 4 - 1, 1, 2, 3 CC (non-malformed
live births)
5.9§
(1.0–40.1)
[12]
Congenital heart
defects
Only beta-blocking agents 25 Mainly first trimester Cohort study 2.76=
(1.79–4.08)
[13]
Severe hypospadias Selective and non-selective
beta-blockers (acebutolol,
atenolol, bisoprolol,
metoprolol, labetalol,
carvedilol, nadolol,
propranolol)
24 - 1, 1, 2, 3, 4 CC (non-malformed
live-born males)
2.02*
(1.11–3.69)
[16]
Severe hypospadias Non selective beta-blockers
(labetalol, carvedilol,
nadolol, propranolol)
16 - 1, 1, 2, 3, 4 CC (non-malformed
live-born males)
3.22*
(1.47–7.05)
[16]
Severe hypospadias Labetalol 12 - 1, 1, 2, 3, 4 CC (non-malformed
live-born males)
3.02*
(1.23–7.44)
[16]
CC case-control study, OR adj adjusted odds ratio
Prevalence ORs adjusted for maternal age and employment status, parity and acute maternal diseases in the second and/or third month of
pregnancy
$Prevalence ORs adjusted for maternal age and parity
#ORs adjusted for maternal diseases
¥ORs adjusted for study centre, maternal age at delivery (\35 years or C 35 years), pre-pregnancy body mass index (underweight/normal or
overweight/obese), and gestational diabetes. Cases with pre-existing type 1 or 2 diabetes mellitus were excluded
§Crude ORs (\5 exposed cases). Women with pre-existing type 1 or 2 diabetes mellitus were excluded
=ORs adjusted for year of birth, maternal age, parity, smoking, and BMI. Women with a diagnosis of diabetes were excluded
*ORs adjusted for site, maternal age, race and ethnicity, parity, fertility treatment, pre-pregnancy diabetes, gestational diabetes, and multiple
birth, ORs were no longer significant after multiple testing using a step-down Bonferroni method
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of congenital anomalies [18]. For the hypospadias analysis,
only male control subjects were used in the analyses.
For the exploratory analysis, we only included regis-
trations in the non-chromosomal non-signal control group
to search for possible new signals not yet reported in the
literature. One by one, all EUROCAT anomaly subgroups
were analysed as cases with a changing control group
consisting of all other registrations. Registrations with
bladder exstrophy, epispadias, prune belly or urethral
valves were excluded from the hydronephrosis group
because the hydronephrosis is secondary to the underlying
anomaly.
2.5 Exposure Definition
The EUROmediCAT registries included in this study
obtain the information on medication exposure from the
mother’s medical files (mostly these are only files relating
to the pregnancy) and from the child’s, except for the
Tuscany registry, which only collects data on medication
use via a questionnaire that is sent to the mother after birth
of the malformed child [22, 23] [Table 1 of the Electronic
Supplementary Material (ESM)]. In the Northern Nether-
lands, pharmacy prescription data were also available.
Norway’s medication exposure data are solely based on the
Norwegian prescription database. The first trimester of
Read the abstract,
not relevant
(n = 355)
Relevant abstracts
(n = 23)
Read the paper
(n = 25)
Including beta-
blockers or CA
(n = 8)
Original
publications
(n = 5)
No mention of beta-
blockers or CA
(n = 17)
Added from
reference
lists
(n = 2)
Review (n = 1)
Meta analyses*(n = 2)
*including Yakoob et
al, 2013
Other (n = 5)
CA not specified (n =1)
Antihypertensives not
specified (n = 2)
Original publications
with signals
(n = 1)
Original publications
without significant results
(n = 1)
Literature search on ‘beta-blockers and congenital anomalies (CA)’
published since Yakoob et al, 2013
(n = 378)
Fig. 1 Flowchart of the literature review
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pregnancy is defined as the period from the first day of the
last menstrual period to the end of gestational week 12.
In this study, exposure was defined as the use of a beta-
blocker (ATC code C07) in the first trimester of pregnancy.
All registries were asked to check whether the beta-
blockers were indeed used in the first trimester of preg-
nancy. We further categorised the beta-blockers into three
groups: non selective beta-blockers (ATC code C07AA),
selective beta-blockers (ATC code C07AB), and combined
alpha- and beta-blockers (ATC code C07AG) (Table 3).
Non-exposure was defined as no use of any beta-blocker in
the first trimester.
2.6 Statistical Analyses
For the signal analysis, we performed logistic regression
analysis with SPSS, Version 23 to calculate ORs and 95%
CIs of exposure to any beta-blocker or to each of the beta-
blocker subgroups for each of the signal anomalies com-
pared with exposure in both control groups. Odds ratios
were adjusted for registry, maternal age (categorised as
age\20 years, 20–24 years, 25–29 years, 30–34 years,
35–39 years andC 40 years), use of other anti-hyperten-
sive medications (ATC codes C02, C03, C08, C09), birth
year (in 5-year intervals) and pregnancy outcome.
Adjustment for pregnancy outcome was performed because
in the total study population the exposure rate to beta-
blockers was lower in TOPFA cases compared with live
births and stillbirths. Additionally, the distribution of
pregnancy outcome was different between the case group
and the two control groups (with the highest TOPFA rate in
the chromosomal control group). Finally, two registers
(Emilia Romagna and Valencia) did not have information
on maternal medication use for TOPFA cases, partly
explaining the lower overall exposure rate in TOPFA cases.
In addition, three sensitivity analyses were performed, in
which we: (1) restricted the analyses to isolated congenital
anomalies (we classified cases as isolated or multiple
congenital anomalies based on the EUROCAT Multiple
Congenital Anomaly Algorithm [18]), (2) used chromoso-
mal controls without a signal anomaly present, or (3)
excluded women who used beta-blockers in combination
with other anti-hypertensive medications.
For the exploratory analysis (in the non-chromosomal
non-signal group), we calculated the ORs of exposure to
any beta-blocker or to each of the beta-blocker subgroups
for each of the EUROCAT subgroups of congenital
anomalies [18]. The analysis was restricted to subgroups
with at least three exposed cases. Odds ratios were adjusted
for registry, maternal age, use of other anti-hypertensive
medications, birth year and pregnancy outcome, as above.
3 Results
In the period 1995–2013, there were 125,835 registrations
of congenital anomalies in the 17 participating EURO-
mediCAT registries (Fig. 2). After exclusions, we had
Table 2 Registries included in the study, study period, number of included registrations and the first trimester exposure rate to beta-blockers
Country Registry Birth years included Number of registrations First trimester exposure to any beta blocker (C07)
n %
Denmark Odense 1995–2012 2509 5 0.20
France Paris 2001–2013 10,521 47 0.45
Isle de la Reunion 2005–2013 3260 6 0.18
Italy Tuscany 1995–2013 11,056 4 0.04
Emilia Romagna 1995–2013 12,513 38 0.30
The Netherlands Northern Netherlands 1995–2013 8991 49 0.54
Switzerland Vaud 1997–2013 4581 17 0.37
Croatia Zagreb 1995–2013 2099 5 0.24
Malta Malta 1996–2013 2116 12 0.57
Belgium Antwerp 1997–2013 7621 4 0.05
Germany Saxony Anhalt 2000–2013 7292 42 0.58
Mainz 1996–2013 2610 1 0.04
United Kingdom Wales 1998–2013 18,840 51 0.27
Norway Norway 2005–2010 10,025 32 0.32
Ireland South East Ireland 2007–2013 865 1 0.12
Spain Basque Country 2005–2013 4428 4 0.09
Valencia Region 2007–2013 7795 2 0.03
Total 1995–2013 117,122 320 0.27
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117,122 registrations for analysis (93%). These registra-
tions were categorised into a signal anomaly group and two
control groups. The signal anomaly group included 49,243
registrations with a congenital anomaly previously reported
to be associated with beta-blocker use in the first trimester
of pregnancy (neural tube defects, cleft lip with or without
CP, CP, congenital heart defects and hypospadias). The
first control group comprised 50,709 registrations with
non-chromosomal non-signal anomalies and the second
control group comprised 17,170 registrations with a chro-
mosomal anomaly.
In this study, the overall exposure to a beta-blocker in
the first trimester of pregnancy was 0.27% (320 exposed
registrations, Table 2). The exposure rate varied between
registries from 0.03% in Valencia to 0.58% in Saxony
Anhalt. In a minority of registrations exposed to beta-
blockers in the first trimester, use of other anti-hypertensive
medications was also registered (n = 55/320, 17.2%, data
not shown). The selective beta-blockers (C07AB) were
most widely used (in 45.3%), followed by the combined
alpha- and beta-blockers (C07AG, in 32.2%, almost
exclusively consisting of labetalol) (Table 3). There were
133 registrations exposed to beta-blockers in the signal
Inclusions
(n = 117,122)
Exclusions (total n = 8,713)
Genetic/teratogenic disorders (n = 5,777)
Timing C07 use unknown (n = 41)
Maternal hypertension & no C0x use (n = 222)
Maternal diabetes/insulin use (n = 1,723)
Maternal epilepsy/antiepileptic use (n = 1,180)
Maternal use of highly teratogenic medication (FDA
class X) (n = 17)
Signal anomalies:
(NTD, CL/P, CP,
CHD, hypospadias)
(n = 49,243)
Control 1:
Non-chromosomal,
non-signal anomalies
(n = 50,709)
Control 2:
Chromosomal
anomalies
(n = 17,170)
Total number of registrations in 17 EUROmediCAT registries
over all or part of the period 1995-2013
(n = 125,835)
Fig. 2 Flowchart of inclusions and exclusions for the signal analysis.
The sum of the separate exclusions is higher than the total number of
exclusions because some cases had more than one exclusion criterion.
CHD congenital heart defect, CL/P cleft lip with or without cleft
palate, CP cleft palate, FDA US Food and Drug Administration, NTD
neural tube defect
Table 3 First trimester exposure to beta-blockers
Type of beta-blocker ATC code n %
Any beta-blocker C07 320 100
Unspecified beta- blockers C07(A) 9 2.8
Non selective beta-blockers C07AA 52 16.3
Propranolol C07AA05 50 15.6
Selective beta-blockers C07AB 145 45.3
Metoprolol C07AB02 55 17.2
Atenolol C07AB03 52 16.3
Bisoprolol C07AB07 23 7.2
Combined alpha- and beta-blockers C07AG 103 32.2
Labetalol C07AG01 101 31.6
Beta-blocker combinations C07B, C07F 13 4.1
2 registrations were exposed to both selective beta-blockers and
combined alpha- and beta-blockers
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anomaly group (0.27%), vs. 47 in the chromosomal con-
trols (0.27%) and 140 in the non-chromosomal non-signal
controls (0.28%) (Table 4).
The results of the signal analysis are shown in Table 4.
We did not find any significantly increased ORs of expo-
sure to beta-blockers for any of the signal anomalies. There
were very few exposures to non-selective beta-blockers,
which resulted in high ORs with large CIs, in particular
when using the chromosomal control group. The next
highest ORs were found for selective beta-blockers and CP,
but the association remained non-significant when com-
pared with both control groups (adjusted OR 2.0, 95% CI
0.8–5.1 for the non-chromosomal non-signal controls and
adjusted OR 1.8, 95% CI 0.6–5.4 for the chromosomal
controls). We did find a significantly decreased OR for
combined alpha- and beta-blockers and hypospadias (ad-
justed OR 0.3, 95% CI 0.1–0.8) using the chromosomal
controls. In our dataset, there were only two registrations
with pulmonary valve stenosis that had been exposed to
beta-blockers and we therefore did not include pulmonary
valve stenosis as a separate subgroup in the signal analysis.
Sensitivity analyses using only isolated cases, or using
chromosomal controls without a signal anomaly, did not
meaningfully change the adjusted ORs (Tables 2 and 3 of
the ESM). The decreased OR for hypospadias and use of
combined alpha- and beta-blockers was no longer signifi-
cant using chromosomal controls without a signal anomaly
present (adjusted OR 0.4, 95% CI 0.1–2.0) (Table 3 of the
ESM). In the last sensitivity analysis, in which we excluded
women who had used beta-blockers and other anti-hyper-
tensive medications, we found a significantly increased OR
for CP after the use of any beta-blocker using non-chro-
mosomal/non-signal controls (adjusted OR 2.1, 95% CI
1.1–4.1) (Table 4 of the ESM).
The results of the exploratory analysis are presented in
Table 5. We analysed 13 EUROCAT congenital anomaly
subgroups with three or more registrations exposed to beta-
blockers and found multi-cystic renal dysplasia (MCRD) to
be significantly associated with first-trimester use of beta-
blockers (adjusted OR 2.5, 95% CI 1.3–5.1, p = 0.008).
This was driven by exposure to combined alpha- and beta-
blockers (adjusted OR 3.8, 95% CI 1.3–11.0, p = 0.012).
4 Discussion
In our large EUROmediCAT dataset, we did not confirm
the signals reported in the literature between the use of
beta-blockers in the first trimester of pregnancy and
specific congenital anomalies. It must be noted that the two
literature signals with the highest ORs [pindolol and neural
tube defects (OR 5.8) and labetalol and ostium secundum
atrial septal defects (OR 5.9)] were based on only two and
four exposed cases, respectively [12, 14]. In our data, CP
was the signal anomaly most likely to be associated with
beta-blocker exposure in the first trimester, but the asso-
ciation was only significant when women who used other
anti-hypertensive medications were excluded. In total, ten
cases with CP (six isolated CP cases, one with multiple
congenital anomalies, and three from Norway where the
EUROCAT Multiple Congenital Anomaly Algorithm was
not applied and therefore could not be classified as either
isolated or multiple) were exposed to beta-blockers. The
signal reported in the literature was based on three CP
cases who were all exposed to oxprenolol (a non-selective
beta-blocker currently used infrequently) and was only
significant when compared with population controls [15].
No other studies have reported an increased risk of con-
genital anomalies after exposure to oxprenolol, but expe-
rience with its use in the first trimester is limited [24].
Oxprenolol was not present in our dataset. The ten CP
cases in our dataset had been exposed to propranolol
(n = 3), atenolol (n = 3), metoprolol (n = 2), labetalol
(n = 1) and a beta-blocker combination (n = 1). None of
the exposed CP cases were also exposed to other anti-
hypertensive medications.
It must be noted that all previous studies in which
associations were found between beta-blocker use and
specific congenital anomalies had certain limitations. Of
the four case-control studies, exposure data were solely
based on retrospective maternal interviews in two studies
of the National Birth Defects Prevention Study [12, 16] and
are therefore subject to recall bias. The other two case-
control studies, both from Hungary, combined prospective
information (from the medical records) with retrospective
data (parental questionnaire, nurse visit to non-responding
families) [14, 15]. The National Birth Defects Prevention
Study used healthy controls, whereas the Hungarian studies
used both population controls without congenital anoma-
lies and patient controls with other defects. For all case-
control studies, information on certain important con-
founders (e.g. folic acid, smoking, alcohol and body mass
index) was lacking. The cohort study used data from the
Swedish Medical Birth Register, which contained infor-
mation on drug use from the midwife interview at the first
antenatal interview (which is before week 12 in 90% of
women) [13]. For this study, all non-diabetic women who
used anti-hypertensive drugs in early pregnancy were
included in the cohort. However, if a women was pre-
scribed beta-blockers, she was only included in the study if
she also had a diagnosis of hypertension (because beta-
blockers can also be prescribed for other conditions).
Therefore, 45% of beta-blocker users were excluded.
In the exploratory analysis, we identified a not previ-
ously reported association between first-trimester exposure
to combined alpha- and beta-blockers and MCRD (adjusted
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Table 4 Results of the signal analysis: odds ratio of exposure to any beta-blocker or to beta-blocker subgroups for each of the signal anomalies
compared to exposure in non-chromosomal, non-signal controls and in chromosomal controls
Non-chromosomal/non-signal controls Chromosomal controls
Any beta-blocker, C07A Number of controls 50,709 17,170
Exposed controls, n (%) 140 (0.28%) 47 (0.27%)
Total cases Exposed cases, n (%) OR adj* (95% CI) OR adj* (95% CI)
Any signal anomaly 49,243 133 (0.27%) 0.9 (0.7–1.2) 0.9 (0.6–1.4)
NTD 3894 6 (0.15%) 0.7 (0.3–1.8) 0.9 (0.4–2.2)
CL/P 3632 11 (0.30%) 1.1 (0.6–2.1) 1.0 (0.5–2.0)
CP 2008 10 (0.50%) 1.7 (0.9–3.4) 1.5 (0.7–3.1)
CHD 32,519 87 (0.27%) 0.9 (0.7–1.2) 0.9 (0.6–1.4)
ASD 7038 28 (0.40%) 1.4 (0.9–2.1) 1.1 (0.7–2.0)
Hypospadias** 8171 20 (0.24%) 0.9 (0.6–1.5) 0.5 (0.2–1.0)
Non-chromosomal/non-signal controls Chromosomal controls
Non-selective beta-blockers,
C07AA
Number of controls 50,598 17,126
Exposed controls, n (%) 29 (0.06%) 3 (0.02%)
Total cases Exposed cases, n (%) OR adj* (95% CI) OR adj* (95% CI)
Any signal anomaly 49,130 20 (0.04%) 0.7 (0.4–1.2) 3.3 (0.8–13.3)
NTD 3889 1 (0.03%) 0.3 (0.0–2.5) 1.5 (0.1–16.6)
CL/P 3624 3 (0.08%) 1.4 (0.4–4.9) 5.4 (0.7–40.6)
CP 2001 3 (0.15%) 2.6 (0.8–8.9) 5.2 (0.9–30.9)
CHD 32,444 12 (0.04%) 0.7 (0.3–1.3) 4.1 (0.8–20.2)
ASD 7012 2 (0.03%) 0.6 (0.1–2.3) 1.2 (0.2–8.7)
Hypospadias** 8153 2 (0.02%) 0.6 (0.1–2.5) 0.4 (0.1–3.1)
Non-chromosomal/non-signal controls Chromosomal controls
Selective beta-blockers,
C07AB
Number of controls 50,666 17,145
Exposed controls, n (%) 59 (0.12%) 22 (0.13%)
Total cases Exposed cases, n (%) OR adj* (95% CI) OR adj* (95% CI)
Any signal anomaly 49,180 64 (0.13%) 1.1 (0.8–1.5) 1.0 (0.6–1.8)
NTD 3891 3 (0.08%) 1.1 (0.3–4.2) 0.7 (0.2–2.7)
CL/P 3627 6 (0.17%) 1.5 (0.6–3.4) 1.1 (0.4–3.1)
CP 2003 5 (0.25%) 2.0 (0.8–5.1) 1.8 (0.6–5.4)
CHD 32,476 39 (0.12%) 1.0 (0.6–1.5) 0.8 (0.4–1.6)
ASD 7024 12 (0.17%) 1.3 (0.7–2.6) 1.0 (0.4–2.5)
Hypospadias** 8163 11 (0.13%) 1.2 (0.6–2.4) 0.7 (0.3–1.9)
Non-chromosomal/non-signal controls Chromosomal controls
Combined alpha- and
beta-blockers, C07AG
Number of controls 50,651 17,142
Exposed controls, n (%) 44 (0.09%) 19 (0.11%)
Total cases Exposed cases, n (%) OR adj* (95% CI) OR adj* (95% CI)
Any signal anomaly 49,156 40 (0.08%) 0.9 (0.6–1.4) 0.6 (0.3–1.1)
NTD 3890 2 (0.05%) 0.9 (0.2–4.5) 1.1 (0.2–4.8)
CL/P 3623 2 (0.06%) 0.7 (0.2–2.8) 0.4 (0.1–1.9)
CP 1999 1 (0.05%) 0.5 (0.1–4.0) 0.3 (0.0–2.3)
CHD 32,467 30 (0.09%) 1.0 (0.6–1.6) 0.7 (0.3–1.3)
ASD 7022 10 (0.14%) 1.6 (0.8–3.2) 1.0 (0.4–2.3)
Hypospadias** 8156 5 (0.06%) 0.7 (0.3–2.0) 0.3 (0.1–0.8)
Bold indicates assocations significant at the 5% level
NTD neural tube defect, CL/P cleft lip with or without cleft palate, CP cleft palate, CHD congenital heart defect, ASD atrial septal defect; n, number
*OR adj, odds ratio adjusted for centre, year of birth, pregnancy outcome, use of other antihypertensives and maternal age
**Control group of hypospadias restricted to male registrations only
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OR 3.8, 95% CI 1.3–11.0, p = 0.012). This association
was based on four isolated MCRD cases from three dif-
ferent registries that had all been exposed to labetalol.
Because we performed many tests, the possibility of a
chance finding cannot be ruled out and it is therefore
important to study this possible association in another
dataset. Furthermore, as the prevalence of non-genetic
MCRD is low (3.91 per 10,000 births in EUROCAT reg-
istries between 2011 and 2015 [25]), the individual risk for
a pregnant women using these medications, if any, will be
low. With a five-fold increased risk, the absolute risk for
MCRD in the offspring is approximately 1 in 500. The
possibility of a small increased risk of MCRD must be
balanced against the benefits of using labetalol, which is
the anti-hypertensive medication of second choice (after
methyldopa) for chronic hypertension in pregnancy [4].
Uncontrolled hypertension might harm both the mother and
the unborn child, but a blood pressure that is too low might
decrease foetoplacental perfusion and could increase the
risk of intrauterine growth retardation [4].
The strength of our study is that we used the very large,
population-based EUROmediCAT database, which con-
tained over 100,000 registrations with a congenital anom-
aly with information on medication use in the first trimester
of pregnancy. A standard coding system is used by all the
registries and ensures detailed and uniform coding of
congenital anomalies [18]. As EUROCAT registries record
all major congenital anomalies born in the areas they cover,
and not just those that are considered important by clini-
cians, the under-reporting and bias are minimalised.
Because we used malformed controls, there is limited
potential for recall or other information bias. A difficulty of
the case-malformed control study design, however, is the
possibility that some of the malformations of the controls
are associated with the exposure of interest, which can lead
to underestimation of the risk (teratogen non-specificity
bias). To protect against this, we have first conducted a
literature review to identify all malformations previously
associated with beta-blocker exposure (signals), which we
excluded from the controls. The controls were divided into
two groups, the first consisting of all non-signal non-
chromosomal controls and the second consisting of all
chromosomal controls. The rationale for using chromoso-
mal controls is that the malformations in these controls
have a known aetiology most likely not related to medi-
cation use. A consequence of the use of malformed controls
is however that the ORs are relative to other malformations
and may therefore not be translated directly to the general
population. The EUROCAT registries ascertain cases with
congenital anomalies in their registration area via multiple
Table 5 Results of the exploratory analysis: odds ratio of exposure to any beta-blocker or to beta-blocker subgroups for each of the EUROCAT
congenital anomaly subgroups compared to exposure in all other EUROCAT congenital anomaly subgroups
Anomaly subgroup Total Any beta-blocker
(C07A)
Non-selective beta-
blocker (C07AA)
Selective beta-blockers
(C07AB)
Combined alpha- and
beta-blockers (C07AG)
n % OR adj (95%
CI)
n % OR adj (95%
CI)
n % OR adj (95%
CI)
n % OR adj (95%
CI)
Talipes equinovarus 4413 12 0.27 1.0 (0.6–1.9) 4 0.09 1.8 (0.6–5.1) 5 0.11 1.0 (0.4–2.6) 3 0.07 0.8 (0.3–2.7)
Multicystic renal dysplasia 1334 9 0.67 2.5 (1.3–5.1) 2 0.15 3 0.22 1.9 (0.6–6.3) 4 0.30 3.8 (1.3–11.0)
Congenital hydronephrosis 4993 9 0.18 0.7 (0.3–1.3) 1 0.02 5 0.10 0.9 (0.4–2.3) 3 0.06 0.7 (0.2–2.3)
Hip dislocation and/or
dysplasia
4670 8 0.17 0.6 (0.3–1.3) 2 0.04 2 0.04 3 0.06 0.9 (0.3–2.8)
Polydactyly 3717 5 0.13 0.5 (0.2–1.1) 1 0.03 1 0.03 2 0.05
Severe microcephaly 957 5 0.52 2.0 (0.8–5.1) 0 0.00 3 0.31 2.9 (0.9–9.5) 0 0.00
Diaphragmatic hernia 896 4 0.45 1.6 (0.6–4.3) 0 0.00 3 0.33 3.0 (0.9–9.9) 0 0.00
Hydrocephalus 1981 4 0.20 0.7 (0.3–2.0) 1 0.05 1 0.05 2 0.10
Vascular disruption
anomalies
2186 3 0.14 0.5 (0.2–1.6) 2 0.09 0 0.00 0 0.00
Oesophageal atresia with or
without tracheo-
oesophageal fistula
750 3 0.40 1.1 (0.3–3.5) 0 0.00 2 0.27 1 0.13
Atresia or stenosis of other
parts of small intestine
426 3 0.70 1.9 (0.6–6.2) 1 0.23 1 0.23 0 0.00
Limb reduction defects 1832 3 0.16 0.6 (0.2–1.9) 2 0.11 1 0.05 0 0.00
Syndactyly 1784 3 0.17 0.6 (0.2–1.9) 0 0.00 3 0.17 1.5 (0.5–4.8) 0 0.00
Bold indicates assocations significant at the 5% level
OR adj, odds ratio adjusted for centre, year of birth, pregnancy outcome, use of other antihypertensives and maternal age
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sources. In addition, all pregnancy outcomes are included,
which is important because terminations of pregnancies
constitute a large proportion of some congenital anomalies
(e.g. neural tube defects) in some registries. The quality of
the EUROCAT data is regularly assessed via data quality
indicators [26].
The registrations with an exposure to beta-blockers were
all validated and confirmed by the registries. However, the
number of congenital anomaly cases exposed to beta-
blockers was relatively low (n = 320). In total, 0.27% of
registrations were exposed to beta-blockers in the first
trimester, which is lower than the 0.6% reported in the
literature (drug utilisation studies in USA and the UK
[6, 7]). It is possible that beta-blockers are prescribed less
in the area covered by the EUROCAT registries that par-
ticipated in this study, but under-registration of beta-
blockers in the EUROmediCAT database is also a possi-
bility, in particular, in the earlier years of our study period,
as hospital records on which the exposure information is
based can be incomplete. Under-ascertainment of some
medications (e.g. antidepressants, anti-asthmatic medica-
tions, antibacterials and ovulation stimulants) in the
EUROmediCAT database is known to occur and this might
also extend to beta-blockers [22, 27]. However, if under-
registration of beta-blocker exposure is present, the
prospective recording of medication exposure is expected
to be similar between cases and malformed controls and
should not lead to major bias. Additionally, we have
adjusted for registry in our analyses to adjust for variation
in exposure ascertainment between the different registries.
There was also no information on medication dose and
duration of medication use.
We were not able to investigate some of the specific
signals reported in the literature: we investigated
hypospadias (and not severe hypospadias because the
degree of severity was not always available) and atrial
septal defects (and not ostium secundum atrial septal
defects). Information about the indication for beta-blocker
prescription was lacking. From the literature, it is known
that beta-blockers are predominantly used to treat hyper-
tension, but can also be prescribed for other conditions
such as migraine prophylaxis, angina, after myocardial
infarction, arrhythmias, atrial fibrillation, chronic heart
failure and essential tremor [28]. In our study population,
there were 53 women with reported migraine as a chronic
disease but only one of them used a beta-blocker. The other
conditions for which beta blockers are prescribed are rare
in women of fertile age. Limited information was available
on possible confounding factors, including folic acid
intake, body mass index, smoking and alcohol use. How-
ever, we did exclude women with diabetes or insulin use
and epilepsy or anti-epileptic drug use, as well as women
who used other highly teratogenic medications.
Finally, we were not able to distinguish between the
effect of the disease (in most cases, this would have been
chronic hypertension) and the effect of the medication
(beta-blocker). It is possible that the likelihood of beta-
blocker use depends on the severity of the hypertension.
Several papers reported that untreated hypertension is
associated with congenital anomalies (e.g. congenital heart
defects, neural tube defects, severe hypospadias, oesopha-
geal atresia) in the offspring [12, 16, 29–32]. The under-
lying pathogenesis could be that untreated chronic
hypertension can lead to uteroplacental insufficiency and
therefore decreased blood flow to the foetus and possible
vascular disruption [30, 33].
Women with chronic hypertension and of child-bearing
age should be counselled about the potential risks of
chronic hypertension and of anti-hypertensive treatment
during pregnancy. Most anti-hypertensive medications are
generally considered safe during pregnancy, with the
exception of angiotensin-converting-enzyme inhibitors and
angiotensin receptor antagonists [34]. These medications
are associated with a characteristic foetopathy (renal failure
and hypocalvaria) when used in the second and third tri-
mesters of pregnancy [35]. However, when these medica-
tions are used in the first trimester of pregnancy, there does
not appear to be an increased risk of structural congenital
anomalies compared with the use of other anti-hyperten-
sive medications [36]. The only beta-blocker with positive
evidence of risk (US Food and Drug Administration former
Letter Category D) is atenolol. Its use in the second tri-
mester of pregnancy has been associated with intrauterine
growth retardation. Severe hypertension in pregnancy
needs to be treated, but there is no consensus as to whether
mild-to-moderate hypertension should also be treated.
First-line agents are methyldopa (a centrally acting antia-
drenergic agent) and labetalol (a combined alpha- and beta-
blocker), but treatment should always be considered on an
individual basis [34, 37, 38]. Other considerations are side
effects or a history of them, potential interactions with
other medications or other diseases, patient preference and
cost [34]. Exposure to beta-blockers late in pregnancy
might be associated with an increased risk of hypotension,
bradycardia, hypoglycaemia, respiratory depression and
lower birth weight in the offspring [39, 40]. Our study
shows that the risk of congenital anomalies after first-tri-
mester exposure to beta-blockers is probably low, but
further studies are needed to confirm this.
5 Conclusion
In this study, no evidence was found that beta-blocker use
in the first trimester of pregnancy is associated with an
increased risk of specific congenital anomalies in the
Beta-Blocker Use in Pregnancy and Risk of Specific Congenital Anomalies
offspring. The new signal we identified between alpha- and
beta-blockers and MCRD needs further investigation.
Future large epidemiological studies, ideally based on
prospective exposure data and information on the indica-
tion of beta-blocker use, are needed to confirm or refute our
findings.
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